CPT code 0582T represents an image-guided, transurethral radiofrequency–generated water vapor thermal ablation procedure to destroy malignant prostate tissue. As an emerging interventional treatment for prostate cancer, the code captures a targeted, device-assisted intraoperative therapy that may affect surgical practice, device utilization, and payer coverage decisions nationwide.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and procedure intent, benchmarks for coverage and reimbursement where available, typical sites of service, and implications for coding and billing workflows. The publication summarizes policy updates relevant to the procedure code, highlights common modifiers and billing considerations, and outlines expected documentation elements tied to intraoperative imaging and needle guidance.

The content is designed for healthcare billing managers, surgical service line leaders, and compliance teams seeking a national-level briefing on coding, payer coverage patterns, and operational impacts associated with CPT code 0582T. Data not available in the input are identified explicitly.